ProMetic Life Sciences (TSE:PLI)‘s stock had its “buy” rating reiterated by analysts at Paradigm Capital in a research note issued to investors on Monday, StockTargetPrices.com reports. They presently have a C$3.75 price target on the stock. Paradigm Capital’s price objective would suggest a potential upside of 132.92% from the company’s current price.
In other ProMetic Life Sciences news, Director Kurt Stefan Victor Clulow bought 229,900 shares of ProMetic Life Sciences stock in a transaction that occurred on Thursday, July 2nd. The stock was purchased at an average price of C$2.32 per share, with a total value of C$533,184.08. Also, Director Simon Geoffrey Best bought 30,000 shares of ProMetic Life Sciences stock in a transaction that occurred on Tuesday, September 8th. The shares were acquired at an average cost of C$1.95 per share, with a total value of C$58,464.00.
PLI has been the subject of a number of other research reports. Scotiabank set a C$3.00 target price on shares of ProMetic Life Sciences and gave the stock an “outperform” rating in a report on Thursday, July 9th. Canaccord Genuity decreased their price target on shares of ProMetic Life Sciences to C$3.50 and set a “buy” rating on the stock in a research note on Monday, August 17th.
ProMetic Life Sciences (TSE:PLI) traded down 6.83% during mid-day trading on Monday, reaching $1.50. The company had a trading volume of 868,749 shares. The company’s 50-day moving average is $1.92 and its 200-day moving average is $2.30. ProMetic Life Sciences has a one year low of $1.40 and a one year high of $2.87. The stock’s market capitalization is $871.08 million.
ProMetic Life Sciences Inc. (TSE:PLI) is a Canada-based biopharmaceutical company. The Company offers solutions in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens. The Company operates through two segments: Therapeutics and Protein Technology. Therapeutics segment is a small molecule drug discovery business. It has lead compounds, namely PBI-4050 indicated for the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. Protein Technology segment contains the financial information of the activities, including BioTherapeutics, Bioseparation and Prion Capture/Pathogen Removal.
By Christopher T. Ellis
Source: The Market Business
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
